Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients
Authors:
- Mariam H Abdel JalilMJMariam H Abdel Jalil
- Ahmed F HawwaAHAhmed F Hawwa
- Patrick J McKiernanPMPatrick J McKiernan
- Michael D ShieldsMSMichael D Shields
- James C McElnayJMJames C McElnay
- 20 December 2013
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 77 (1) , 130-140
Abstract
Aims: To build a population pharmacokinetic model that describes the apparent clearance of tacrolimus and the potential demographic, clinical and genetically controlled factors that could lead to inter‐patient pharmacokinetic variability within children following liver transplantation.Methods: The present study retrospectively examined tacrolimus whole blood pre‐dose concentrations (n = 628) of 43 children during their first year post‐liver transplantation. Population pharmacokinetic analysis was performed using the non‐linear mixed effects modelling program (nonmem) to determine the population mean parameter estimate of clearance and influential covariates.Results: The final model identified time post‐transplantation and CYP3A5*1 allele as influential covariates on tacrolimus apparent clearance according to the following equation: urn:x-wiley:03065251:media:bcp12174:bcp12174-math-5001 where TVCL is the typical value for apparent clearance, TPT is time post‐transplantation in days and the CYP3A5 is 1 where *1 allele is present and 0 otherwise. The population estimate and inter‐individual variability (%CV) of tacrolimus apparent clearance were found to be 0.977 l h−1 kg−1 (95% CI 0.958, 0.996) and 40.0%, respectively, while the residual variability between the observed and predicted concentrations was 35.4%.Conclusion: Tacrolimus apparent clearance was influenced by time post‐transplantation and CYP3A5 genotypes. The results of this study, once confirmed by a large scale prospective study, can be used in conjunction with therapeutic drug monitoring to recommend tacrolimus dose adjustments that take into account not only body weight but also genetic and time‐related changes in tacrolimus clearance.Keywords
This publication has 35 references indexed in Scilit:
- Population Pharmacokinetics of Tacrolimus in Pediatric Liver Transplantation: Early Posttransplantation ClearanceTherapeutic Drug Monitoring, 2011
- Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEMComputer Methods and Programs in Biomedicine, 2011
- Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part IIClinical Pharmacokinetics, 2010
- Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part IClinical Pharmacokinetics, 2010
- Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplantBritish Journal of Clinical Pharmacology, 2009
- Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patientsBritish Journal of Clinical Pharmacology, 2007
- Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patientsBritish Journal of Clinical Pharmacology, 2007
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Covariate Effects on the Apparent Clearance of Tacrolimus in Paediatric Liver Transplant Patients Undergoing Conversion TherapyClinical Pharmacokinetics, 2001
- Evaluation of a height/plasma creatinine formula in the measurement of glomerular filtration rate.Archives of Disease in Childhood, 1982